{"id":"jtz-951","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The apelin-APJ axis plays a role in vascular function, cardiac contractility, and metabolic regulation. By blocking APJ signaling, JTZ-951 may improve cardiac function and reduce pathological remodeling in heart failure. The drug is being developed primarily for cardiovascular indications where APJ antagonism could provide therapeutic benefit.","oneSentence":"JTZ-951 is a selective antagonist of the apelin receptor (APJ) that modulates cardiovascular and metabolic pathways.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:44.163Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heart failure with reduced ejection fraction (HFrEF)"}]},"trialDetails":[{"nctId":"NCT04027517","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis.","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2019-01-15","conditions":"Anemia of Chronic Kidney Disease","enrollment":172},{"nctId":"NCT02805244","phase":"PHASE1","title":"Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis","status":"COMPLETED","sponsor":"Akros Pharma Inc.","startDate":"2016-06","conditions":"Anemia of Chronic Kidney Disease","enrollment":6},{"nctId":"NCT02581124","phase":"PHASE1","title":"Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease","status":"COMPLETED","sponsor":"Akros Pharma Inc.","startDate":"2015-10","conditions":"Anemia of Chronic Kidney Disease","enrollment":10},{"nctId":"NCT01971164","phase":"PHASE1","title":"Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease","status":"COMPLETED","sponsor":"Akros Pharma Inc.","startDate":"2013-05","conditions":"Anemia of Chronic Kidney Disease","enrollment":29},{"nctId":"NCT01978587","phase":"PHASE1","title":"Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease","status":"COMPLETED","sponsor":"Akros Pharma Inc.","startDate":"2013-10","conditions":"Anemia in Chronic Kidney Disease","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["enarodustat"],"phase":"phase_3","status":"active","brandName":"JTZ-951","genericName":"JTZ-951","companyName":"JW Pharmaceutical","companyId":"jw-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JTZ-951 is a selective antagonist of the apelin receptor (APJ) that modulates cardiovascular and metabolic pathways. Used for Heart failure with reduced ejection fraction (HFrEF).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}